January 22, 2014
1 min read

HT lessened risk for repeat knee, hip replacement surgery

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Hormone therapy was associated with approximately 40% reductions in repeat surgeries after a total knee arthroplasty or total hip arthroplasty, according to data derived from a population-based retrospective cohort study.

“We have shown that [HT] use for at least 6 months after primary arthroplasty is associated with a significant reduction in prosthesis failure of up to almost 40% after lower limb total joint arthroplasty. [HT] for at least 1 year appeared related to further reduction in failure rates to about 50% of that in [HT] non-users,” researchers wrote.

Data from 2,700 HT users were collected from the United Kingdom within the General Practice Research Database and matched with 8,100 non-users who underwent a primary total knee arthroplasty or total hip arthroplasty from 1986 to 2006.

The patients were followed for a median of 3.3 years after primary arthroplasty, representing 43,481 person-years (32,845 non-HT users; 10,636 HT users).

Data indicated that HT use for at least 6 months was associated with a significant reduction in risk for asymptomatic failure (HR=0.62; 95% CI, 0.41-0.94). Similarly, HT use for at least 12 months was associated with further reductions in failure risk (HR=0.48; 95% CI, 0.29-0.78), researchers wrote.

These data cannot be implemented into clinical practice until further research is complete, they wrote.

Disclosure: The researchers report no relevant financial disclosures. The independent research was commissioned by the National Institute for Health Research and unrestricted educational grants from Merck, Sharp & Dohme, Novartis and Southampton Rheumatology Trust.